ORKA Oruka Therapeutics, Inc. Common Stock Loading... : Bullish and Bearish Analyst Opinions
Loading chart...
Top Calls
Feed
13:38
May 19
May 19
Buy SYRE, ORKA, and APGE as the triple combination appears undervalued relative to alternatives, with potential upside from oncology inclusion.
HIGH
12:41
May 19
May 19
Avoid SYRE, ORKA, and APGE due to overvaluation vs. a private competitor with superior bispecific platform, broader pipeline, and lower trial risk; the author questions the durability of their clinical data and rationale for separate companies.
HIGH
16:10
May 07
May 07
The tweet lists four biotech tickers with no directional commentary or forward-looking thesis, merely sharing a link without expressing a bullish or bearish view.
HIGH
23:51
May 01
May 01
Adam May highlights his successful short call on ORKA, which is down 40% since his premarket tweet, reinforcing his bearish stance against the stock.
HIGH
18:07
May 01
May 01
Adam May notes ORKA dropped 30% from Monday's high and links to SYRE, but provides no forward-looking opinion or trade thesis.
HIGH
16:43
Apr 29
Apr 29
Bearish view on ORKA on ABBV's advancing extended half-life IL23, adding another competitor that reduces ORKA's market opportunity in a crowded space.
HIGH
10:57
Apr 29
Apr 29
Bearish view on ORKA as a me-too psoriasis drug with no meaningful innovation; high valuation ($6B) relies on broken payor system and is unsustainable long-term.
HIGH
01:14
Apr 29
Apr 29
Bearish view on ORKA at current valuation because its $6B market cap at Phase 2a implies peak sales exceeding Bimzelx (~$3B), an absurd premium for an unproven asset with no near-term revenue.
HIGH
23:51
Apr 28
Apr 28
Avoid ORKA and SYRE because recent data readouts only confirmed expected results after stocks already rallied >100%, indicating no new catalyst and potential overvaluation.
HIGH
13:42
Apr 28
Apr 28
Short/avoid ORKA, APGE, and NTLA; bullish survey data is flawed because it ignores generic competition that will erode the advantage of sparser dosing.
HIGH
21:41
Apr 27
Apr 27
The author argues that chronic disease drugs going generic will be far cheaper than NTLA's expensive gene therapy, undermining its value while criticizing Big Pharma profit motives.
HIGH
18:16
Apr 27
Apr 27
Bearish view on ORKA due to me-too efficacy, intense biosimilar competition, limited psoriasis TAM, and a market cap implying >2.5x peak sales at P2a—fundamentally unjustified versus comps like Bimzelx.
HIGH
18:11
Apr 27
Apr 27
Bearish view on ORKA due to me-too IL-23 psoriasis drug facing entrenched branded and biosimilar competition, inferior efficacy vs Skyrizi, minimal differentiation (fewer injections not worth premium), and rich valuation (>2.5x peak sales at P2a stage).
HIGH
17:06
Apr 27
Apr 27
Speaker mentions having opinions on ORKA's launch setup but does not state direction or reasoning; merely acknowledges a pending discussion.
LOW
15:40
Apr 27
Apr 27
Bearish view on ORKA due to lack of competitive differentiation against entrenched biosimilars and branded alternatives; implied exit value is too low versus S&P returns.
HIGH
15:35
Apr 27
Apr 27
Bearish view on $ORKA due to unfavorable competitive landscape (safer biosimilars, entrenched brands) and unattractive risk/reward for a post-P3 exit compared to S&P returns.
HIGH
15:12
Apr 27
Apr 27
Adam May asks for a counter-pitch on ORKA at a $6B valuation without expressing his own forward-looking directional view.
LOW
13:09
Apr 27
Apr 27
Short ORKA based on speaker’s claimed track record of successful shorts in similar names (NTLA, HIMS, VKTX, IOVA).
HIGH
12:02
Apr 27
Apr 27
Doctor reports clinical success with an existing biosimilar, implying ORKA’s Phase 3 readout is still pending; no directional trade view stated.
LOW
11:35
Apr 27
Apr 27
Bearish view on ORKA based on a medical professional's direct clinical experience that existing psoriasis treatments are already highly effective, undermining the need for ORKA's offering.
HIGH
11:14
Apr 27
Apr 27
Short ORKA due to phase 2a data that merely matches existing therapies (Skyrizi, Bimzelx) while facing biosimilar competition and a $7B market cap that implies unjustified premium for a heavily served indication.
HIGH
18:23
Apr 26
Apr 26
Buy ORKA ahead of tomorrow's Phase 2a data; speaker expects positive readout on PASI100 response rate based on proven IL23p19 efficacy, though valuation near $5B adds risk.
HIGH
About ORKA Analyst Coverage
Buzzberg tracks ORKA (Oruka Therapeutics, Inc. Common Stock) across 1 sources. 1 bullish vs 2 bearish calls from 1 analysts. Sentiment: mixed to bearish. 22 total trade ideas tracked.